Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Epistaxis in HHT
NCT01485224Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Nov 2011
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in hereditary hemorrhagic telangiectasia (HHT), sponsored by IRCCS San Matteo Foundation. Started Nov 2011; status: completed.
02
Drugs
thalidomide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT01485224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485224.